Biomedical Engineering Reference
In-Depth Information
108. Childers, N. K.; Miller, K. L.; Tong, G.; Llarena, J. C.; Greenway, T.; Ulrich, J. T., et al. Adju-
vant Activity of Monophosphoryl Lipid A for nasal and Oral Immunization with Soluble or
Liposome-associated Antigen.
Infect. Immun.
2000,
68,
5509-5516.
109. Doherty, T. M.; Olsen, A. W.; van Pinxteren, L.; Andersen, P. Oral Vaccination with Sub-
unit Vaccines Protects Animals Against Aerosol Infection with
Mycobacterium tuberculosis
.
Infect. Immun.
2002,
70,
3111-3121.
110. O'Hagan, D. T.; Singh, M. Microparticles as Vaccine Adjuvants and Delivery Systems.
Expert
Rev. Vaccines
2003,
2,
269-283.
111. Pandey, R. S.; Sahu, S.; Sudheesh, M. S.; Madan, J.; Kumar, M.; Dixit, V. K. Carbohydrate
Modified Ultrafine Ceramic Nanoparticles for Allergen Immunotherapy.
Int. Immunopharm.
2011,
11,
925-931.
112. Van Der Lubben, I. M.; Konings, F. A.; Borchard, G.; Verhoef, J. C.; Junginger-He, C. In vivo
Uptake Of Chitosan Microparticles by Murine Peyer's Patches: Visualization Studies Using Con-
focal Laser Scanning Microscopy and Immunohistochemistry.
J. Drug Target.
2001,
9,
39-47.
113. Canon, M. J.; O'Brien, T. J.; Underwood, L. J.; Crew, M. D.; Bondurant, K. L.; Santin, A.
D. Novel Target Antigens for Dendritic Cell-based Immunotherapy Against Ovarian Cancer.
Expert Rev. Anticancer Ther.
2002,
2
.
114. Nowakowski, A.; Wang, C.; Powers, D. B.; Amersdorfer, P.; Smith, T. J.; Montgomery, V. A.;
Sheridan, R.; Blake, R.; Smith, L. A.; Marks, J. D. Potent Neutralization of Botulinum Neuro-
toxin by Recombinant Oligoclonal Antibody.
PNAS
2002,
99,
11346-11350.
115. Kwong, B.; Liu, H.; Irvine, D. J. Induction of Potent Anti-tumor Responses While Eliminating
Systemic Side Effects via Liposome-anchored Combinatorial Immunotherapy.
Biomaterials
2011,
32,
5134-5147.
116. Pandey, R. S.; Dixit, V. K. Evaluation of ISCOM Vaccines for Mucosal Immunization Against
Hepatitis B.
J. Drug Del.
2010,
18,
282-291.
117. Salman, H. H.; Gamazo, C.; Campanero, M. A.; Irache, J. M. Salmonella-like Bioadhesive
Nanoparticles.
J. Controlled Release
2005,
106,
1-13.
118. Qurashi, T.; Blair, H. S.; Allen, S. J. Studies on Modified Chitosan Membranes. I. Preparation
and Characterization.
J. Appl. Polym. Sci.
1992,
46,
255-261.
119. Shin, H.; Jo, S.; Mikos, A. G. Biomimetic Materials for Tissue Engineering.
Biomaterials
2003,
24,
4353-4364.
120. Richardson, S. C.; Kolbe, H. V.; Duncan, R. Potential of Low Molecular Mass Chitosan as
a DNA Delivery System: Biocompatibility, Body Distribution and Ability to Complex and
protect DNA.
Int. J. Pharm.
1999,
178
.
121. Muzzarelli, R.; Baldassarre, V.; Conti, F. Biological Activity of Chitosan: Ultrastructural
Study.
Biomaterials
1988,
9,
247-252.
122. Nishimura, K.; Nishimura, S.; Nishi, N. Immunological Activity of Chitin and its Derivatives.
Vaccine
1984,
2,
93-99.
123. Otterlei, M.; Varum, K. M.; Ryan, L.; Espevik, T. Characterization of Binding and TNF-alpha-
inducing Ability of Chitosans on Monocytes: The Involvement of CD14.
Vaccine
1994,
12,
232-285.
124. Pappineau, A.; Hoover, D.; Knoor, D.; Farkas, D.
Food Biotechnology
; Marcel and Dekker:
New York, 1991.
125. Lee, K. Y.; Kwon, I. C.; Kim, Y. H. Preparation of Chitosan Self-aggregates as a Gene Delivery
System.
J. Controlled Release
1998,
51,
213-220.
126. Aspden, T. J.; Mason, J. D.; Jones, N. S. Chitosan as a Nasal Delivery System: The Effect of
Chitosan Solutions on In vitro and In vivo Mucociliary Transport Rates in Human Turbinates
and Volunteers.
J. Pharm. Sci.
1997,
86,
509-513.
